DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for adenosquamous lung carcinoma — screening already-approved drugs against its 47-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAdenosquamous lung carcinoma maps to a 47-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Structures already discussed alongside adenosquamous lung carcinoma in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Structure of L1196M Mutant Anaplastic Lymphoma Kinase — Crizotinib has a real, experimentally solved structure in complex with this target (PDB 2YFX, 1.7 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet vghdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2YFX · 1.7 Å · ligand Crizotinib (VGH). Experimental structure, not a prediction.
What the evidence adds up to
A retrospective analysis of 103 patients with adenosquamous lung carcinoma diagnosed between 1977 and 1986 found that 94% of patients (100% of men, 79% of women) were smokers. Among the 95 patients with known stage at diagnosis, 11% had local stage, 28% regional, and 61% distant stage. Overall 1-, 2-, and 5-year survival for the 103 patients was 27%, 18%, and 8%, respectively. Local stage had the best survival, with more than 50% of patients alive at 4 years; regional stage had a median survival of 10 months but no 5-year survivors; distant stage had a median survival of 5 months, with one patient (2%) alive at 3 years. The frequency of adenosquamous carcinoma increased two- to three-fold over the study period.
A separate 1993 study of 75 archived cases classified as adenosquamous carcinoma found that independent review by three pathologists using the 1982 WHO criteria yielded acceptance rates of 65%, 28%, and 65%. Concordance between each pair of pathologists was 49%, 61%, and 43%, indicating poor agreement. Cases not accepted as adenosquamous fell into other non-small cell lung cancer subtypes. The study concluded that the reproducibility of the adenosquamous diagnosis is poor, and physicians should be aware of this limitation.
A 2023 study of patients who underwent surgical resection for pathological stage I non-small cell lung cancer compared 40 patients with adenosquamous carcinoma to 598 with adenocarcinoma and 131 with squamous cell carcinoma. The adenosquamous group had a 5-year overall survival of 66.7% and a 5-year recurrence-free survival of 44.9%, with a recurrence rate of 32.5% (13/40 patients). Multivariable Cox regression identified adenosquamous histology as an independent risk factor for recurrence (hazard ratio 2.473, 95% CI 1.328–3.367; P = 0.0004). High serum carcinoembryonic antigen levels (hazard ratio 5.962) and vascular invasion (hazard ratio 4.899) were also risk factors. Recurrences tended to be distant, including in the brain.
A 2003 study of 60 surgical cases of adenosquamous carcinoma at a single institution reported that all studies have emphasised the poorer prognosis of adenosquamous carcinoma compared to adenocarcinoma or squamous cell carcinoma. No survival numbers or response rates are given in that abstract. What remains missing are prospective trials designed specifically for adenosquamous carcinoma, reliable diagnostic criteria that pathologists can agree on, and any data on systemic therapies — no abstract in this set reports on chemotherapy, targeted therapy, or immunotherapy outcomes.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Clinical Oncology · 1992 · 19 citations
The Increasing Recognition of Adenosquamous Lung Carcinoma (1977–1986)
AbstractA retrospective analysis of the data in the tumor registry on all 103 patients with adenosquamous lung carcinoma diagnosed and treated at our center between 1977 and 1986 was performed. The history of tobacco use was available for 100 patients (72 men and 28 women). Ninety-four percent of the patients (100% of men and 79% of women) were smokers, suggesting that adenosquamous carcinoma may be a Kreyberg I type of lung carcinoma. The gender, race, and age distributions in adenosquamous carcinoma were similar to other histologic subtypes of lung carcinoma. Patients less than 45 years old constituted 10%; 45-54 years old, 24%; 55-64 years old, 34%; 65-74 years old, 25%; and greater than 75 years, 7%. In the 95 patients whose stage at the time of diagnosis was known, 11% had local stage; 28%, regional; and 61%, distant stage. The 1-, 2- and 5-year survival of the 103 patients were 27%, 18%, and 8%, respectively. Survival was related to stage. Local stage had the best survival, and greater than 50% of patients were alive at 4 years. Regional stage had an intermediate median survival of 10 months but no survivors at 5 years. Distant stage had the worst median survival (5 months), and one patient (2%) was alive at 3 years. There was a significant increase (two- to three-fold) in the frequency of adenosquamous carcinoma over the 10-year study period, 1977-1986.
The Accuracy of the Histological Classification of Lung Carcinoma and Its Reproducibility: A Study of 75 Archival Cases of Adenosquamous Carcinoma
AbstractThe classification of lung carcinoma into a small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC), is highly reproducible. There are few studies on the reproducibility of subtyping NSCLC, with anecdotal reports on the subtype of adenosquamous carcinoma. We undertook a study of 75 cases archived as adenosquamous carcinoma. All cases were accepted as NSCLC on independent review by three pathologists utilizing the 1982 World Health Organization (WHO) classification criteria. The acceptance rate of adenosquamous carcinoma by the three pathologists was 65%, 28%, and 65%. Cases not accepted as adenosquamous fell into the different subtypes of NSCLC, with a concordance rate between each pair of pathologists of 49%, 61% and 43%, indicating poor agreement between pathologists. The study confirms the high reproducibility of the classification into SCLC and NSCLC; it shows poor concordance for all subtypes of NSCLC with poor reproducibility of diagnosis of adenosquamous carcinoma as specified by the 1982 WHO classification. Physicians dealing with lung carcinoma should be aware of this limitation of classification.
Japanese Journal of Clinical Oncology · 2023 · 5 citations
Clinicopathologic study of stage I adenosquamous carcinoma of the lung
AbstractOBJECTIVE: Adenosquamous carcinoma of the lung is a characteristic tumor that has both adenocarcinoma and squamous cell carcinoma components. Adenosquamous carcinoma is reported to have an aggressive clinical course, but its clinicopathological features and prognosis are unclear in the early stage. METHODS: Patients who underwent surgical resection for pathological stage I non-small cell lung cancer between April 2009 and December 2014 were retrospectively reviewed. Preoperative and postoperative data, histologic characteristics and outcomes of patients with adenosquamous carcinoma (n = 40) were compared to adenocarcinoma (n = 598) and squamous cell carcinoma (n = 131) patients. Factors affecting prognosis, particularly on recurrence, were assessed via Cox regression analyses. RESULTS: Patients with adenosquamous carcinoma had a worse prognosis than did patients with adenocarcinoma and squamous cell carcinoma in terms of 5 year overall (66.7%) and recurrence-free survival rates (44.9%), as well as a significantly higher recurrence rate (13/40 patients, 32.5%). Multivariable Cox regression analysis for recurrence-free survival rates revealed that the histology of adenosquamous carcinoma was an independent factor for recurrence (hazard ratio: 2.473, 95% confidence interval: 1.328-3.367; P = 0.0004). High serum carcinoembryonic antigen levels (hazard ratio: 5.962) and vascular invasion (hazard ratio: 4.899) were identified as risk factors for recurrence, and patients with adenosquamous carcinoma tended to have distant relapses, such as in the brain. CONCLUSIONS: Early-stage adenosquamous carcinoma of the lung is a histological type associated with severe prognosis and postoperative recurrence, often in distant sites, in approximately one-third of cases. High serum carcinoembryonic antigen levels and vascular invasion might be risk factors of recurrence.
Adenosquamous Carcinoma of the Lung: Surgical Results at Taichung Veterans General Hospital
AbstractAdenosquamous carcinoma of the lung is an uncommon malignancy. All studies have emphasized the poorer prognosis of adenosquamous carcinoma compared to either adenocarcinoma or squamous cell carcinoma of the lung. In this study, we analyzed 60 cases of adenosquamous carcinoma of the lung at our institute, and discuss, in this report, the histogenesis and biologic behavior of the malignancy.
Muller Journal of Medical Sciences and Research · 2017 · 0 citations · open access
Crizotinib in treatment of lung cancer
AbstractLung cancer is one of the most common malignancies and is the leading cause of cancer-related mortality throughout the world. Despite advances in surgery and chemotherapy, survival is still poor. Crizotinib is an oral inhibitor of multiple kinases, including anaplastic lymphoma kinase (ALK), and is indicated in the treatment of patients with locally advanced or metastatic? non small cell lung carcinoma (NSCLC) harboring ALK mutation as a targeted therapy. This is short drug review of crizotinib in the treatment of advanced lung cancer.
Co-occurrence of lung adenocarcinoma and pulmonary fibrosis in a patient: A comprehensive case study and review of existing literature on the successful utilization of nintedanib
AbstractBoth lung carcinoma and idiopathic pulmonary fibrosis (IPF) have an adverse prognosis, and the co-existence of both diseases is not uncommon. We introduce a clinical case involving a patient diagnosed with concurrent occurrences of lung adenocarcinoma and IPF. The patient underwent a therapeutic regimen comprising the administration of docetaxel in conjunction with nintedanib. This treatment approach was followed by the sustained utilization of maintenance nintedanib over an extended duration, leading to substantial enhancements in the patient’s quality of life. Furthermore, we discuss the few therapeutic options concerning this clinical challenge and possible future therapeutic options.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
